Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. - Wikidata - wikimedia - TriplyDB

Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.

Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.

http://www.wikidata.org/entity/Q40272840

about

Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications Epigenetic targeting of ovarian cancer stem cells The influence of cis-regulatory elements on DNA methylation fidelity.Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.Epigenetic regulation of cancer-associated genes in ovarian cancer.Progressive silencing of p14ARF in oesophageal adenocarcinoma.H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma Targeting the enhancer of zeste homologue 2 in medulloblastoma.MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy.Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells.Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer.Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype.Minireview: epigenetic changes in ovarian cancer.Epigenetic aberrations during oncogenesis.Role of epigenomics in ovarian and endometrial cancers.Modulation of gene expression in ovarian cancer by active and repressive histone marks.Epigenetic perspectives on cancer chemotherapy response.Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.Biology and Treatment of Rhabdoid Tumor.Epigenetic alternations and cancer chemotherapy response.Wenxia Changfu Formula () induces apoptosis of lung adenocarcinoma in a transplanted tumor model of drug-resistance nude mice.Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.Epigenetic biomarkers in the diagnosis of ovarian cancer.Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.Stat4 limits DNA methyltransferase recruitment and DNA methylation of the IL-18Ralpha gene during Th1 differentiation.Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus.Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma.The involvement of lncRNAs in the development and progression of pancreatic cancer.MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway.Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.Endometriosis Malignant Transformation: Epigenetics as a Probable Mechanism in Ovarian Tumorigenesis.

P2860

Q26769604-A957F7C8-019A-4E41-9A3D-0EC13B16500B Q33621141-74D3693F-CBEB-4DAF-9243-CE9473479BA0 Q33741828-3D50422F-BE1F-455D-881C-68DF549ABA9A Q33884564-721607E5-18EB-4347-BD06-B7BB4E7A5891 Q34135466-15F6DC98-0488-4204-88D7-F9ACB9917394 Q34193554-71A9147E-8D5D-4B7A-866E-A814C70D2C00 Q34305438-AB250BA4-E9A6-43D4-B854-8910A8149D05 Q34569371-E126D1D4-0869-4032-B961-0AF28EB05CC0 Q34643691-23D49F7A-2794-4312-A657-FE40823D5D08 Q34874813-A27DDA3C-A121-442C-9C2B-5141424E8277 Q34995366-B7E21C50-9807-4CE0-AC4C-2A3C90F82353 Q35876813-D867CC91-22BC-4BA3-B93C-22FCC7360D4E Q36032753-F4FB9839-8B5C-4A5B-8388-3EDDA1E3075D Q36225822-817B5688-7766-48CC-9ACC-960AB003D422 Q36709245-D5E261BE-D71A-4F48-B3D9-1BB772886AC5 Q36840255-B2815689-40D0-4509-9F1E-884B2E57D66D Q36967368-96CCBCE0-7D60-43ED-8120-47A5F8C990F5 Q36998193-728ED6E8-9D92-4FAB-A642-19D837FD59EF Q37033992-FD201D94-81C0-4060-8551-C23DD051F347 Q37328836-8F4C63B5-0E5C-43CF-8537-794A9F510839 Q37830385-AE12270A-0A48-42E9-AA04-F773ED728480 Q37961734-85280288-1557-4DCB-81D3-7F7D58727FB2 Q37962015-9E099231-177C-4BF2-ABBE-4B8DCD31E962 Q38209574-6078ED46-A0C7-43B4-A332-26343A53D09D Q38544386-619A535A-6CC2-4B2F-B948-6ED58F74BE52 Q38582867-6DA8D432-423F-4447-9CDD-EE3BD63C0589 Q38680431-B6B74F75-5DA1-4396-8E06-C81ADD1870ED Q38811827-2A6B2AA5-87E2-47B2-A974-B3247A1AD023 Q38940136-94A4809C-346D-4F56-8F08-9B8FA73BA07C Q39453522-F94D1D71-2725-4B84-A5E7-192D8AE0C8A4 Q39921991-869FBAA9-D6A9-4B28-A0FC-5BE383FDBDA6 Q39996922-B75F47F8-6EE1-4211-8EEC-3286C544EBBA Q42130325-51F89D4E-C378-4FB9-A1FE-42680CC33E22 Q42575787-48004F1A-DCAA-42D0-BD54-6B999919C1FE Q46294277-FBCEAD75-0D49-4E6B-B553-BBAF719BF4B1 Q46406967-5DD3703B-B784-4A38-B056-8A12E17D76E8 Q47624410-E2A680D6-0660-474E-B671-658DAC8149A2 Q47696168-486C3624-ECD3-4A29-A30A-8C18B9607D92 Q52342542-788D04B8-4176-4126-8F98-EA61BEDC3A78 Q55418713-FEDBB057-7AC3-4A46-A924-9658EB65F690

P2860

Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.

http://www.wikidata.org/entity/Q40272840

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Dominant-negative histone H3 l ...... ant phenotype in cancer cells.

@en

type

label

Dominant-negative histone H3 l ...... ant phenotype in cancer cells.

@en

prefLabel

Dominant-negative histone H3 l ...... ant phenotype in cancer cells.

@en

P1433

Q40272840-72C424E5-7F51-40FB-AD4C-11362BC7D1F4

P1476

Q40272840-1396877F-A7D5-466D-AE94-1E92799A4F4C

P2093

Q40272840-0B092F0A-4D26-4F20-820B-82BB70BF2C03

Q40272840-0DEAC265-9985-417C-87B2-F2309B1B9986

Q40272840-18D225DD-1CFD-4913-9B4E-6FCE06059F77

Q40272840-30FA14CF-8E8E-49EB-909A-1FD6024F2EE9

Q40272840-72C3EC71-C266-4140-93AD-4736E25CE782

Q40272840-77C195C3-1256-43DD-9D86-8E7AB7AD088F

Q40272840-84BFFFF9-C668-47F4-A288-85FDEF73E2F9

Q40272840-AB71F540-6BCE-417F-A17C-2DDAAAEBEE69

Q40272840-B64AA0D8-290A-419D-8215-756011FE9553

Q40272840-BDF4C1FF-CDA8-4B94-BAB0-F194DCD923AC

P304

Q40272840-4B98DE1C-C20B-434F-91B1-9FD202DC458F

P31

Q40272840-5E2C840B-199D-4FA8-A038-5B66FADFB5C3

P356

Q40272840-1A355B15-6AF9-4AEA-88A1-20E43429C184

P407

Q40272840-6087E8D0-3324-450F-A525-BD47D72C644E

P433

Q40272840-CE589D1E-3491-408C-8408-46E90F58D49E

P478

Q40272840-654E8086-E8C1-4F75-914A-5678F406B485

P577

Q40272840-ED963B5D-E129-4303-AE6F-A9F48608E536

P5875

Q40272840-A3086512-A56E-4576-A77A-7883F1FDD3B6

P698

Q40272840-90A89C89-DFB1-4668-8A6C-2631FEA3D0EE

P921

Q40272840-D2DD1029-AC17-420E-82DA-AEC0F4CEA9CA

P356

0008-5472.CAN-05-3575

P1433

Cancer Research

P1476

Dominant-negative histone H3 l ...... ant phenotype in cancer cells.

@en

P2093

Adam Golas

http://www.w3.org/2001/XMLSchema#string

Annie P Moseman

http://www.w3.org/2001/XMLSchema#string

Curtis Balch

http://www.w3.org/2001/XMLSchema#string

Eleanor G Zuhowski

http://www.w3.org/2001/XMLSchema#string

Jason A Starkey

http://www.w3.org/2001/XMLSchema#string

John S Montgomery

http://www.w3.org/2001/XMLSchema#string

Kate M Brannon

http://www.w3.org/2001/XMLSchema#string

Kenneth P Nephew

http://www.w3.org/2001/XMLSchema#string

Merrill J Egorin

http://www.w3.org/2001/XMLSchema#string

Milos Novotny

http://www.w3.org/2001/XMLSchema#string

P304

5582-5591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-05-3575

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7041659

http://www.w3.org/2001/XMLSchema#string

P698

16740693

http://www.w3.org/2001/XMLSchema#string

P921